These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30569245)

  • 41. Safety, Tolerability, and Pharmacokinetics of the Novel Adenosine A
    Tayama T; Ishiuchi M; Sugiyama K; Oka Y; Maeda H; Nagata Y; Hruska M; Kagawa Y
    Clin Pharmacol Drug Dev; 2023 Aug; 12(8):801-809. PubMed ID: 36683291
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers.
    Erpenbeck VJ; Vets E; Gheyle L; Osuntokun W; Larbig M; Neelakantham S; Sandham D; Dubois G; Elbast W; Goldsmith P; Weiss M
    Clin Pharmacol Drug Dev; 2016 Jul; 5(4):306-13. PubMed ID: 27310331
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers.
    Bani M; Colantoni A; Guillaume M; Macchi F; Moroni G; Persiani S
    Br J Clin Pharmacol; 2000 Oct; 50(4):338-49. PubMed ID: 11012557
    [TBL] [Abstract][Full Text] [Related]  

  • 45. First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll-like Receptors 7 and 8, in Healthy Volunteers.
    Yamakawa N; Tago F; Nakai K; Kitahara Y; Ikari S; Hojo S; Hall N; Aluri J; Hussein Z; Gevorkyan H; Maruyama T; Ishizaka S; Yagi T
    Clin Pharmacol Drug Dev; 2023 Apr; 12(4):363-375. PubMed ID: 36219471
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
    Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
    Barbier AJ; Hilhorst M; Van Vliet A; Snyder P; Palfreyman MG; Gawryl M; Dgetluck N; Massaro M; Tiessen R; Timmerman W; Hilt DC
    Clin Ther; 2015 Feb; 37(2):311-24. PubMed ID: 25438724
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects.
    Yoon S; Shin D; Lee H; Jang IJ; Yu KS
    Drug Des Devel Ther; 2015; 9():5033-49. PubMed ID: 26357467
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers.
    Pawsey S; Wood M; Browne H; Donaldson K; Christie M; Warrington S
    Drugs R D; 2016 Jun; 16(2):181-91. PubMed ID: 26987975
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
    Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
    Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety, Tolerability, and Pharmacokinetic Characteristics of a Novel Nonopioid Analgesic, VVZ-149 Injections in Healthy Volunteers: A First-in-Class, First-in-Human Study.
    Oh J; Lee S; Kim A; Yoon J; Jang K; Lee DH; Cho S; Lee SR; Yu KS; Chung JY
    J Clin Pharmacol; 2018 Jan; 58(1):64-73. PubMed ID: 28815639
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
    Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
    Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers.
    Cardinal M; Kantaridis C; Zhu T; Sun P; Pittman DD; Murphy JE; Arkin S
    J Thromb Haemost; 2018 Sep; 16(9):1722-1731. PubMed ID: 29908043
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of DS-1211, a tissue-nonspecific alkaline phosphatase inhibitor.
    Maruyama S; Visser H; Ito T; Limsakun T; Zahir H; Ford D; Tao B; Zamora CA; Stark JG; Chou HS
    Clin Transl Sci; 2022 Apr; 15(4):967-980. PubMed ID: 35021269
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
    Banfield C; Scaramozza M; Zhang W; Kieras E; Page KM; Fensome A; Vincent M; Dowty ME; Goteti K; Winkle PJ; Peeva E
    J Clin Pharmacol; 2018 Apr; 58(4):434-447. PubMed ID: 29266308
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects.
    Shen Z; Gillen M; Miner JN; Bucci G; Wilson DM; Hall JW
    Drug Des Devel Ther; 2017; 11():2077-2086. PubMed ID: 28744099
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety, tolerability and pharmacokinetic profile of single and multiple oral doses of arterolane (RBx11160) maleate in healthy subjects.
    Saha N; Moehrle JJ; Zutshi A; Sharma P; Kaur P; Iyer SS
    J Clin Pharmacol; 2014 Apr; 54(4):386-93. PubMed ID: 24242999
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics, pharmacodynamics, tolerability and prediction of clinically effective dose of ACT-774312: A novel CRTH2 antagonist.
    Géhin M; Lott D; Farine H; Issac M; Strasser D; Sidharta P; Dingemanse J
    Basic Clin Pharmacol Toxicol; 2019 Jun; 124(6):711-721. PubMed ID: 30589994
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, SUVN-502, in Healthy Young Adults and Elderly Subjects.
    Nirogi R; Mudigonda K; Bhyrapuneni G; Muddana NR; Goyal VK; Pandey SK; Palacharla RC
    Clin Drug Investig; 2018 May; 38(5):401-415. PubMed ID: 29380267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.